Company: ACHV
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059297
Chunk: 53

Company: ACHIEVE LIFE SCIENCES, INC.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 53
---
 in control or if such Involuntary Termination is required by the merger agreement, purchase agreement or other instrument relating to such change in control, or such Involuntary Termination is made at the express request of the other party or parties to the transaction constituting such change in control, each of which events is referred to as a Change in Control Termination. Upon such a Change in Control Termination, we will be obligated to pay Mr. Oki 24 months of his then-current base salary, plus a sum equal to 24 months of his average monthly bonus earnings, where such average is calculated over the 24-month period immediately preceding Mr. Oki’s separation from services and based on Mr. Oki’s bonuses paid in such 24-month period. In addition, our payment of monthly COBRA premiums as described above will be for up to 24 months instead of up to 12 months. Notwithstanding the terms of any of our equity compensation plans or any agreement in connection with such plans, upon a Change in Control Termination, all vesting restrictions, if any, including performance vesting restrictions, will immediately lapse on all of Mr. Oki’s compensatory equity effective as of his separation from service.

All termination benefits in the event of an Involuntary Termination or Change in Control Termination are subject to Mr. Oki’s execution, delivery and non-revocation of a general release of all litigation and other claims against us and our affiliates.

40

SECURITY OWNERSHIP OF CER TAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information with respect to the beneficial ownership of our common stock by the following persons as of April 15, 2025, except as otherwise noted in the footnotes to the table: • each person, entity or group who we know to beneficially own five percent or more of our voting securities; • each of our directors and director nominees; • each of our NEOs identified in the Summary Compensation Table; and • all of our directors and executive officers as a group. The address of each beneficial owner listed in the table is c/o Achieve Life Sciences, Inc., 22722 29 th Drive SE, Suite 100, Bothell, Washington 98021. The percentages in the table below are based on 34,685,072 shares of our common stock outstanding as of April 15, 2025. Except as indicated in the footnotes to the table and pursuant to applicable community property laws, to our